GlobeNewswire Inc.··NaTeva, Blackstone Life Sciences Team Up on $400M Deal for GI Drug duvakitug
Teva and Blackstone Life Sciences announce $400 million four-year funding agreement to develop duvakitug for inflammatory bowel disease, supporting Teva's specialty pharma pivot.
SNYTEVAmonoclonal antibodyclinical development